IC
PTGX icon

Ikarian Capital’s Protagonist Therapeutics PTGX Stock Holding History

Ikarian Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-100,000
Closed -$4.84M – 175
2025
Q1 		$4.84M Buy
+100,000
New +$4.19M 0.6% 36
2023
Q3 		– Sell
-200,000
Closed -$5.52M – 166
2023
Q2 		$5.52M Sell
200,000
-11,400
-5% -$285K 0.88% 37
2023
Q1 		$4.86M Buy
+211,400
New +$3.55M 1.1% 29
2022
Q2 		– Sell
-160,700
Closed -$3.81M – 192
2022
Q1 		$3.81M Buy
160,700
+33,800
+27% +$952K 0.5% 50
2021
Q4 		$4.34M Buy
126,900
+65,800
+108% +$2.08M 0.65% 40
2021
Q3 		$1.08M Buy
+61,100
New +$2.6M 0.08% 155

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's PTGX Position: Q1 2025 in Review

Ikarian Capital sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 70,000 shares — an estimated $2.93M sold.

Ikarian Capital first reported a position in PTGX in Q4 2019 and held it in 5 quarters. The position peaked at $7.31M in Q4 2023. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

  • Ikarian Capital reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ikarian Capital sold 70,000 Protagonist Therapeutics shares in Q1 2025, an estimated $2.93M.
  • Ikarian Capital first reported a position in Protagonist Therapeutics in Q4 2019 and held it in 5 quarters.
  • Ikarian Capital's Protagonist Therapeutics position peaked at $7.31M in Q4 2023.
  • 275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.